Schizophrenia, Combination therapy for mania

Adult: 10 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 10mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day.

Preventing recurrence in bipolar disorder

Adult: 10 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 10mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day.

Monotherapy for mania

Adult: 15 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 15 mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day control of agitation and disturbed behaviour in schizophrenia or mania.

•  Acute Myocardial Infarction
• Bradycardia
• Recent Heart Surgery
• Severe Hypotension
• Sick Sinus Syndrome
• Unstable Angina

Bone-marrow depression, hyper eosinophilic disorders, low leucocyte count, low neutrophil count, myeloproliferative disease, paralytic ileus.

Cautions, Further Information

CNS and respiratory depression with intramuscular use blood pressure, pulse and respiratory rate should be monitored for at least 4 hours after intramuscular injection, particularly in those also receiving a benzodiazepine or another antipsychotic (leave at least one hour between administration of olanzapine intramuscular injection and parenteral benzodiazepines).

GENERAL SIDE-EFFECTS

Common or very common Anticholinergic syndrome,appetite increased, arthralgia, asthenia, eosinophilia, fever, glycosuria, oedema, sexual dysfunction.

Uncommon Abdominal distension, alopecia, breast enlargement, diabetes mellitus, dysarthria, epistaxis, memory loss, photosensitivity reaction, urinary disorders.

Rare or very rare Hepatic disorders, hypothermia, pancreatitis, rhabdomyolysis, thrombocytopenia.

Specific Side-Effects

Hypersomnia

Uncommon

Diabetic coma, ketoacidosis, oculogyration

Rare or very rare

Withdrawal syndrome

Frequency not known

Cardiovascular event, erythema, fall, gait abnormal, hallucinations, pneumonia.

Store in a cool and dry place

10×10 Tablets

Monitoring Requirements

Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs, patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly, fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly, patients taking olanzapine should have fasting blood glucose tested at baseline, after one months’ treatment, then every 4–6 months.